Shares of Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following ...

Novo Nordisk appoints Maziar Mike Doustdar as the new CEO to tackle falling sales and shares amid stiff competition in the ...

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Novo Nordisk has lowered its sales and profit forecasts for the second time this year due to competitive pressures in the ...

Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...

Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...

Shares in Novo Nordisk plunged as much as 30% after the Danish drugmaker cut its guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy weight-loss drug.

Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...